Equities

Gentian Diagnostics ASA

Gentian Diagnostics ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)41.00
  • Today's Change-2.60 / -5.96%
  • Shares traded25.00
  • 1 Year change+3.02%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in NOK

The one analyst offering a 12 month price target expects Gentian Diagnostics ASA share price to rise to 67.00 in the next year from the last price of 41.00.
High63.4%67.00
Med63.4%67.00
Low63.4%67.00

Earnings history & estimates in NOK

On Feb 16, 2023, losses of -0.300 per share.
The next earnings announcement is expected on Feb 14, 2025.
Average growth rate-20.97%
Gentian Diagnostics ASA reported annual 2023 losses of -0.25 per share on Feb 09, 2024.
Average growth rate+25.67%
More ▼

Revenue history & estimates in NOK

of 37.80m.
Average growth rate+5.75%
Gentian Diagnostics AS had revenues for the full year 2023 of 142.35m. This was 27.18% above the prior year's results.
Average growth rate+27.13%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.